Burning Rock Biotech vs Codexis
Burning Rock Biotech and Codexis are similar in size: $75.1m and $70.4m of revenue in their latest fiscal years. Codexis grew faster (18.6% against 4.7%). Burning Rock Biotech kept more of each dollar of sales as profit: a net margin of -10.3% against -62.5%.
| Latest fiscal year | Burning Rock BiotechBNR, 2025 | CodexisCDXS, 2025 |
|---|---|---|
| Revenue | $75.1m | $70.4m |
| Revenue growth | 4.7% | 18.6% |
| Net income | −$7.7m | −$44.0m |
| Operating margin | — | -59.3% |
| Net margin | -10.3% | -62.5% |
| Return on equity | -9.9% | -74.9% |
| Free cash flow | −$4.7m | −$23.8m |
| Cash | $68.4m | $50.8m |
| Total debt | $243,097 | $42.2m |
| Debt to equity | — | 83.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 146 |
| Market value | $115m | $97.3m |
| Price vs our value range | — | — |
| Moat score | — | 23 (Weak) |
| Insider trades, 12 months | 8 buys, 0 sales | 0 buys, 37 sales |